Stocks of Gilead Sciences, Inc (NASDAQ:GILD) traded higher last session on Wall Street, up 0.26% to $97.20.
GILD stock price is now 5.51% away from the 50-day moving average and 21.99% away from the 200-day moving average. The market capitalization of the company currently stands at $121.14B.
With the price target enhanced from $87 to $113, Morgan Stanley Upgraded its rating from Equal-Weight to Overweight for Gilead Sciences, Inc (NASDAQ: GILD). , while ‘Wolfe Research’ rates the stock as ‘Outperform’
In other news, ANDREW DICKINSON, Officer bought 142,180 shares of the company’s stock on Jan 31 ’25. The stock was bought for $13,822,740 at an average price of $97.22. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 31 ’25, Officer MERDAD V PARSEY bought 184,683 shares of the business’s stock. A total of $18,098,989 was incurred on buying the stock at an average price of $98.00. A total of 0.10% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $62.07 and a high of $98.90. As of last week, the company has a debt-to-equity ratio of 1.26, a current ratio of 1.26, and a quick ratio of 1.10. According to the stock market information, the enterprise value for the company is $137605038080, which is based on a 1095.83 price-to-earnings ratio, a 190.58 price-to-earnings-growth ratio, and a beta of 0.20. The fifty day moving average price for GILD is $92.123 and a two-hundred day moving average price translates $79.67595 for the stock.
The latest earnings results from Gilead Sciences, Inc (NASDAQ: GILD) was released for 2024-09-30. The net profit margin was 0.45% and return on equity was 0.62% for GILD. The company reported revenue of $7.54 billion for the quarter, compared to $7.05 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.01 percent.
